How did BTAI's Q1 2024 EPS surprise analysts?
4/11/2025 02:17pm
Bioxcel Therapeutics (BTAI) reported an EPS surprise of -$0.17 for Q1 2024, which was a significant negative surprise compared to analysts' expectations. The company's diluted EPS for the quarter was -$0.87, indicating that the company's performance was below market expectations.
|code|Ticker|Name|Date|EPS Surprise|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|BTAI|BTAI.O|Bioxcel Therapeutics|2023 Q2|-0.08|-1.83|186|
|BTAI|BTAI.O|Bioxcel Therapeutics|2023 Q3|-0.27|-1.72|186|
|BTAI|BTAI.O|Bioxcel Therapeutics|2023 Q4|0.15||186|
|BTAI|BTAI.O|Bioxcel Therapeutics|2024 Q1|-0.17|-0.87|186|